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Abstract
Background: There is growing evidence that Chlamydia pneumoniae may be involved in the pathogenesis of
atherosclerosis, as several studies have demonstrated the presence of the organism in atherosclerotic lesions. C.
pneumoniae  infections, which are especially persistent infections, have been difficult to diagnose either by
serological methods or isolation of the organism from the tissue. Nucleic Acid Amplification tests (NAATs) has
emerged as an important method for detecting C. pneumoniae. Inspite of high prevalence of C. pneumoniae specific
antibodies in coronary heart disease patients, direct detection of C. pneumoniae in circulating blood of coronary
artery disease (CAD) patients by sensitive nucleic acid amplification tests nested PCR (nPCR), multiplex PCR
(mPCR) has not been carried out is required. Further correlation of the presence of C. pneumoniae in blood of
CAD patients with C. pneumoniae specific IgA and IgG antibodies, which may indicative of the status of infection
with the progression of atherosclerosis. This will help in order to prepare strategies for the antibiotic intervention
to avoid the progression towards CAD.
Methods: Venous blood was obtained from 91 CAD patients and 46 healthy controls. Nucleic acid amplification
tests viz. nested -, semi-nested – and multiplex PCR were used for detection of C. pneumoniae. ELISA carried out
prevalence of C. pneumoniae specific IgG and IgA antibodies.
Results: 29.67% (27/91) patients were positive for C. pneumoniae using nested PCR. The sensitivity and specificity
of semi-nested and multiplex PCR were 37.03%, 96.96% and 22.22%, 100% with respect to nested PCR. Positive
nPCR patients were compared with presence of C. pneumoniae specific IgA, IgA+IgG and IgG antibodies. Among
27 (29.67%) nPCR C. pneumoniae positive CAD patients, 11(12%) were IgA positive, 13(14.2%) were IgA+IgG
positive and only1 (1.1%) was IgG positive. A significant presence of C. pneumoniae was detected in heavy smokers,
non-alcoholics and with family histories of diabetes and blood pressure group of CAD patients by nPCR.
Conclusion: The results indicate synergistic association of C. pneumoniae infection and development of CAD
with other risk factors. We also detected increased positivity for C. pneumoniae IgA than IgG in nPCR positive
CAD patients. Positive nPCR findings in conjunction with persisting high C. pneumoniae specific antibody strongly
suggest an ongoing infection.
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Background
Coronary artery disease (CAD) is a major cause of mor-
bidity and mortality in humans and is predicted to be the
leading cause of death in the world [1]. Acquired meta-
bolic abnormalities like hypercholesterolemia, diabetes
mellitus are major risk factors associated with CAD,
besides inheritance. These factors on compounding with
pathogens like C. pneumoniae, Helicobacter pylori and
Cytomegalovirus intensifies the magnitude of risk
impending towards CAD [2,3]. Several reports have sug-
gested a role of chronic C. pneumoniae infection in patho-
genesis of CAD and other atherosclerotic syndromes [4,5].
C. pneumoniae has been established as an important path-
ogen that causes infections of upper and lower respiratory
tract [6-8]. C. pneumoniae has a large amount of factual
data that suggests that the organism plays a contributory
role in atherosclerosis [4]. These data are based on serol-
ogy, animal model studies, direct detection of the organ-
ism in atherosclerotic lesion, and preliminary clinical
trials showing improved outcome among patients treated
with antibiotics [9-11]. Changes in habits (Drinking,
smoking, junk foods) and habituation (urbanization,
migration) also conferred their role in extending predis-
position towards CAD [12].
It is reported that Indians have the highest risk of CAD
and the prevalence of CAD in India has recently been esti-
mated to be 11% [13]. In a study from India, species-spe-
cific C. pneumoniae IgG antibodies were detected in 73.7%
of CHD patients by immunocomb assay [14]. The high
prevalence of C. pneumoniae specific serum immunoglob-
ulins is suggestive of an alarming condition of infection in
the country and calls for an immediate requirement to
ascertain the status of infection in CAD patients.
Detection of C. pneumoniae in atheromatous plaques was
shown by PCR, transmission electron microscopy (TEM),
in situ hybridization (ISH) and Immunohistochemistry
(IHC) [15], however, the detection of C. pneumoniae in cir-
culating blood by nucleic acid amplification tests is tech-
nically more feasible approach since discrepancies have
been reported for detection in vessel walls of specimen
[16]. In both the mouse and rabbit models of C. pneumo-
niae-induced atherosclerosis, C. pneumoniae has been
detected in the blood prior to its appearance in atherom-
atous lesions of major blood vessels, including the aorta
and coronary arteries [17].
Therefore in the present study detection of C. pneumoniae
was carried out in venous blood of CAD patients using
various nucleic acid amplification tests (NAATs) viz;
nested PCR (nPCR), semi-nested PCR (snPCR) and multi-
plex PCR (mPCR). Our first aim was thus to find a reliable
NAAT test that would give help in precise detection of C.
pnuemoniae in blood. Our second aim was to quantify the
minimum amount of DNA required for detection of C.
pneumoniae. As increased IgA antibody levels often reflects
an active or persistent infection, whereas IgG levels reflect
only a previous or past infection with C pneumoniae [18],
our third aim was to correlate the presence of C. pneumo-
niae in blood of CAD patients with C. pneumoniae specific
IgA and IgG antibodies. The early detection of C. pneumo-
niae in venous blood by a sensitive, reliable and economic
assay will help to improve patient management in India.
Methods
Enrollment of patients
During the period from March 2005 – 2006, 91 patients
(72 males and 19 females) attending Cardiology out
patient department of Safdarjung hospital, suspected of
coronary artery disease and subsequently admitted for
angioplasty were enrolled for the study. In addition, 46
age matched healthy controls were also included in the
study. The study received clearance from Ethical Commit-
tee of Safdarjung hospital. Prior written consent was also
obtained from all the patients as well as controls. A
detailed questionnaire including reasons for referral to
cardiology department, age, sex, smoking habit, alcohol
consumption and history of heart disease, blood pressure,
or diabetes was maintained for all the patients included in
the study.
Collection of samples
Venous blood (5 ml) was collected in heparinized tubes
(Heparin-Hi Media, Mumbai, India) and 2 ml in non-
heparinized tubes from CAD patients and controls. Serum
was separated and kept at -20°C until analyzed for the
detection of C. pneumoniae specific IgA and IgG.
DNA extraction
5 ml of blood sample was incubated with equal amount
of sample buffer containing 30 mM Tris-HCl [pH 8.0], 30
mM EDTA, 150 mM NaCl, 0.5% SDS, 0.5% Triton X-100,
5% Tween-20, and proteinase K at 55°C for 3 hrs. Subse-
quently samples were extracted with phenol: chloroform:
isoamyl alcohol (25: 24: 1), followed by precipitation of
DNA in ice-cold absolute ethanol and were resuspended
in autoclaved distilled water. Quantitation of DNA was
performed on a spectrophotometer (Thermo Spectronic,
Rochester, New York, USA) and was checked for its integ-
rity on 0.5 % agarose gel before primer specific amplifica-
tion.
Primer selection
The major outer membrane protein (Omp1) and 16S
rRNA genes were the targets for amplification of C. pneu-
moniae  specific nucleic acid for snPCR and nPCR. The
sequences for primer pairs of 16SrRNA Multiplex
(mPCR), Semi-nested Omp1  (snPCR) and 16SrRNA
nested PCR (nPCR) were taken from published literatureBMC Infectious Diseases 2007, 7:48 http://www.biomedcentral.com/1471-2334/7/48
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[19-21]. In mPCR assay, the 16SrRNA coding genes of
three Chlamydial species viz:C. trachomatis, C. pneumoniae
and C. psittaci were selected. The primers (Microsynth,
Switzerland) were synthesized and were tested for purity
by HPLC. The sequences of primers are listed in Table 1.
Nucleic Acid Amplification Tests (NAATs)
All PCR reactions were performed on a Peltier based ther-
mocycler (Eppendorf, Germany), amplicon were electro-
phoresed on agarose gels stained with ethidium bromide
(0.5 pg/ml) and visualized on Gel documentation system
(Alpha Imager, San Laendro, USA). Positive and negative
controls were included in all PCR reactions.
i) Multiplex PCR (mPCR)
mPCR was used for the detection of C. pneumoniae, C. tra-
chomatis and C. psittaci in blood of CAD patients and con-
trols. The PCR final reaction volume of 50 µl contained
0.2 µM primers, 0.2 mM deoxynucleotide triphosphates,
lX PCR buffer (10 mM Tris [pH 8.3], 50 mM KCI, 2.5 mM
MgCl2, 0.01% gelatin), and 1 U of Taq polymerase (Invi-
togen, USA). Samples were subjected to 30 cycles of dena-
turation (94°C, 1 min), annealing (55°C, 1 min), and
extension (72°C, 1 min). Amplified product was electro-
phoresed on 1.2% agarose.
ii) Nested PCR (nPCR)
For performing nested PCR, amplicon contamination pre-
vention measures were strictly applied as described by
Kwok and Higushi [22].
a) Omp1 snPCR
Omp1 snPCR antisense primer was same for both outer
and inner sets of reactions. In the first step PCR was per-
formed in 50 µl reaction containing 0.25 uM primers, 0.2
mM deoxynucleotide triphosphates, lX PCR buffer (10
mM Tris [pH 8.3], 50 mM KCI, 2.5 mM MgCl2, 0.01% gel-
atin), and 1 U of Taq polymerase (Invitogen, USA). Sam-
ples were subjected to 35 cycles of denaturation (94°C, 1
min), annealing (55°C, 1 min), and extension (72°C, 1
min) for amplification of outer pairs. In the second step,
5 µl of sample from step one was amplified using same
conditions in 30 cycles
nPCR
The first step of nPCR was performed in a 50 µl reaction
mixture, containing 0.20 uM primers, 0.2 mM deoxynu-
cleotide triphosphates, lX PCR buffer (10 mM Tris [pH
8.3], 50 mM KCI, 3.0 mM MgCl2, 0.01% gelatin), and 1 U
of Taq polymerase (Invitogen, USA). Cycling parameters
were of 30 cycles of denaturation at 94°C for 30 s, anneal-
ing at 60°C for 60 s and elongation at 72°C for 90 s. In
the second step, 5 ul of first step PCR product of 570 bp
was amplified in 30 cycles of denaturation at 94°C for 30
s, annealing at 68°C for 60 s and elongation at 72°C for
60 s. We further evaluated the efficiency of nPCR to detect
C. pnuemoniae in lowest amount of patient DNA. Various
concentrations of DNA viz. 25, 50, 75 and 100 ng were
taken and amplification was carried out as described
above.
Table 1: Details of oligonucleotide sequences used for detection of C. pneumoniae by NAATs.
Assays
Target
Format
Assay
Primers Amplicon size (bp) cycle
1. 16SrRNA Multiplex
C.pneumoniae
5' TGA CAA CTG TAG AAA TAC AGC 3' 463 bp 30
5' TAA ATA TCC TCT CTC CGC 3'
C.psittaci
5' TGA CCG CGG CAG AAA TGT CGT 3'
5' GAC GTT TCC TCT CTC CGC 3'
C.trachomatis
5' TGA CCG CGG CAG AAA TGT CGT 3'
5'GGC GTT CCC TCT CTC CGC 3'
2. Omp1 Semi-nested
(1st pair)
5' TGC CAA CAG ACG CTG GCG T 3' 35
5' TCT GAA CTG ACC AGA TAC GT 3'
(2nd pair)
5' TGC GAC CAT CAA TTC TCA TG 3' 360 bp 30
5' TCT GAA CTG ACC AGA TAC GT 3'
3. 16SrRNA Nested
(1st pair)
5' GCT GGC GGC GTG GAT G 3' 30
5' CGA CAC GGA TGG GGT TG 3'
(2nd pair)
5' TGG CGG AAG GGT TAG TAG TA 3' 570 bp 30
5' CCC TTT TCC CCA TCT ATC C 3'BMC Infectious Diseases 2007, 7:48 http://www.biomedcentral.com/1471-2334/7/48
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Serology
The detection of C. pneumoniae specific IgG and IgA was
performed using an ELISA kit (R-Biopharm AG, Germany)
as per manufacturer's instructions. This is done on the
basis of index number, which is obtained by dividing the
absorbance for the sample by the calculated average cut
off control value. An index value >1.1 is predicted as C.
pneumoniae positive; 0.9–1.1 as equivocal; <0.9 as C. pneu-
moniae negative. All calculations have been done consid-
ering only true positive C. pneumoniae cases.
Statistical analysis
SPSS version 12.0 for Windows (SPSS Inc., Chicago, USA)
was used for statistical testing. All PCR results were dichot-
omized as positive or negative. For comparing diagnostic
assays, the Fisher-exact statistic for binary related variables
was used. For the comparisons of results, pairs of assays,
the two highest-ranking diagnostic assays were compared
with all others by using McNamara's test of two related
variables. Simultaneously, an alpha level of 0.05 was set
as the level of significance. To evaluate baseline clinical
characteristics binary logistic regression was used.
Results
The mean age for CAD patients and healthy controls were
comparable (54.19 and 51.34 yrs respectively). Out of 91
CAD patients, 72 were males and 19 were females, while
in 46 healthy controls 36 were males and 10 females.
Results of agarose gel electrophoresis on amplified prod-
ucts for mPCR, snPCR and nPCR are shown in Figures 1,
2, and 3. In mPCR, positivity for C. pneumoniae was higher
in CAD patients (6.5%) compared to 0% in healthy con-
trols (p = 0.08). The specificity of mPCR for C. pneumoniae
was confirmed using positive control DNA of C. trachom-
atis and C. psittaci. In snPCR and nPCR positivity for C.
pneumoniae  was higher in CAD patients 13.8% and
29.67% respectively in comparison to healthy controls
with percentage positivity 4.3%, 10.86% respectively (p =
0.125; p = 0.031) (Table 2). The sensitivity and specificity
of snPCR as compared to nPCR were 37.03%, 96.96% and
the positive predictive value (PPV) and negative predictive
value (NPV) were 79.01 and 29.03 respectively, which
were significant (p = 0.001) (Table 3). When mPCR was
compared with nPCR the sensitivity and specificity were
22.22%, 100% respectively, and the PPV and NPV were
100, 76.19 respectively, (p > 0.001) (Table 3). In quanti-
tative nPCR as low as 25 ng of patient DNA showed
amplification at 30 cycles (Figure 4).
Taking nPCR as gold standard the baseline clinical charac-
teristics age, sex, smoking habit, alcohol consumption
and family history of CAD, blood pressure and diabetes
were compared in C. pneumoniae positive CAD patients
and controls. No significant variation in % positivity for
C. pneumoniae was observed in male v/s female, how-
ever, a significant difference in % positivity for C. pneu-
moniae in heavy smokers CAD patients (p = 0.019) was
observed when compared to healthy controls with odds
ratio of 4.57, 2.63 and 1.19 in heavy smokers, occasional
smokers and never smoker respectively (Table 4). Percent
Positivity for C. pneumoniae among non-alcoholic CAD
patients was significantly higher (p = 0.026) compared
with the other groups, the odds ratio for heavy, occa-
sional, never alcoholic was 1.24, 1.60 and 4.75 respec-
tively. No significant difference in % positivity of C.
pneumoniae was detected in patients with family history
of heart disease, high BP or diabetes; the odds ratio was
2.64, 2.91 and 3.00 respectively.
Further, two variables, mainly smoking habit, alcohol
consumption was also compared in C. pneumoniae posi-
tive CAD patients (Figure 5, 6). In CAD patients, % posi-
tivity for C. pneumoniae was significantly higher in heavy
smokers group as compared to occasional or never
smoker (p = 0.017, 0.003) (Figure 5). In non-alcoholic
CAD patients, % positivity for C. pneumoniae was signifi-
Table 3: Comparison of nPCR (gold standard) with snPCR and mPCR.
NAAT Sensitivity (%) Specificity (%) PPV NPV Prevalence (%) P Value
snPCR Vs nPCR 37.03 96.96 83.33 79.01 29.03 0.001*
mPCR Vs nPCR 22.22 100 100 76.19 29.67 >0.001*
* The above table shows the performance of nested PCR with respect to semi nested and multiplexes PCR. The level of significance (P Value) has 
been calculated using McNamara's test.
Table 2: Prevalence of C. pneumoniae in CAD patients using 
NAATs.
NAATs CAD Pt.
C.p +ve
(N = 91)
Healthy Control
C.p +ve
(N = 46)
P Value
nPCR 27 (29.67) 5 (10.86) 0.031*
Omp1snPCR 12 (13.18) 2 (4.3) 0.125
mPCR 6 (6.5) 0 (0) 0.08
Figure in parenthesis indicates % positivity,
C.p = C. pneumoniae,
* Statistical significance of % positivity of C. pneumoniae in CAD 
patients compared to healthy controls.BMC Infectious Diseases 2007, 7:48 http://www.biomedcentral.com/1471-2334/7/48
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cantly higher (p = 0.001) (Figure 6) compared to occa-
sional (p = NS) or heavy alcoholic.
In (Figure 7) nPCR positivity in blood of CAD patients
were compared with positivity for C. pneumoniae specific
IgA, IgA+IgG and IgG antibodies. Out of 29.67% nPCR C.
pneumoniae positive CAD patients, 12% were positive for
C. pneumoniae specific IgA, 14.2% for both IgA+IgG and
1.1% for IgG. In controls, out of 10.8% nPCR positive
individuals, 4.3% were positive for C. pneumoniae specific
IgA and also for IgA+IgG antibodies. None of the nPCR
positive controls had C. pnuemoniae specific IgG antibod-
ies.
Discussion
Chronicity of persistent infection of C. pneumoniae may be
a major factor associated with the pathophysiological
changes leading to CAD. In India there is an urgent need
for sensitive methods that could detect and provide direct
evidence of C. pneumoniae in CAD patients and identify
chronic/persistent infections. Serology may be more pre-
dictive in detecting a previous or an ongoing C. pneumo-
niae  infection, while PCR is an alternative for a rapid
identification of this pathogen in circulating blood
[23,24].
Although NAATs offer the promise of exquisite sensitivity,
theoretically allowing for detection of a single organism
in a clinical sample, both false-negative and positive
results can and do occur. The reported positivity rates for
detection of C. pneumoniae DNA by various NAATs ranged
from 0% to 60% [25]. Reports suggest that there is poor
concordance between different laboratories, as only 25%
agree on one specimen and there is no correlation
between the detection rates and the sensitivity of NAATs
used.
Keeping these observations in mind all good laboratory
practice guidelines were followed according to Kwok and
Higushi [22]. Among NAATs used in this study, nPCR
showed higher sensitivity and specificity than mPCR or
Quantitative nPCR for 16SrRNA gene specific for C. pneu- moniae Figure 4
Quantitative nPCR for 16SrRNA gene specific for C. pneu-
moniae. Amplified product was electrophoresed on 1.2 % 
agarose gel yielding a 570 bp product. Lane 1 100 bp ladder, 
Lane 2 negative control, Lane 3,4,5 and 6, CAD patients 
DNA 100, 75, 50, 25 ng respectively.
 1    2    3   4 5   6
570 bp
snPCR for Omp1 C. pneumoniae specific gene Figure 2
snPCR for Omp1 C. pneumoniae specific gene. Amplified 
product was electrophoresed on 1.5% agarose gel yielding a 
360 bp product. Lane1 positive control, Lane 2&3 DNA of 
CAD patients, Lane 4, 100 bp ladder, Lane 5, negative con-
trol.
 1     2     3     4     5
360bp
mPCR for 16SrRNA C. pneumoniae specific gene Figure 1
mPCR for 16SrRNA C. pneumoniae specific gene. Amplified 
product was electrophoresed on 1.2% agarose gel yielding a 
463 bp product. Lane 1 Positive control, Lane 2, 4, 5 DNA of 
CAD patients, Lane 3 negative control and Lane 6, 100 bp 
ladder.
  1     2     3    4     5     6
463 bp
nPCR for 16SrRNA gene specific for C. pneumoniae Figure 3
nPCR for 16SrRNA gene specific for C. pneumoniae. Ampli-
fied product was electrophoresed on 1.2 % agarose gel yield-
ing a 570 bp product. Lane 1 Negative control, Lane 2 100 bp 
ladder Lane 3 positive control, Lane 4, 5, 6, CAD patients 
DNA
 1   2  3   4  5   6
570 bpBMC Infectious Diseases 2007, 7:48 http://www.biomedcentral.com/1471-2334/7/48
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snPCR with its percentage positivity of 29.67%. Our
results also indicate that nPCR is highly sensitive to detect
as low as 25 ng of DNA from CAD patients. In control
group (consisted of hospital-based workers) 10.8 % posi-
tivity for C. pneumoniae was detected by nPCR and this
could have reflected an overestimation of the occurrence
of C. pneumoniae in a healthy population since hospital-
based workers are more likely to be exposed to individuals
with respiratory tract infections.
Previously it has been reported that increased IgA anti-
body levels reflects an active or persistent infection,
whereas IgG levels reflect only a previous or past infection
with C pneumoniae [26]. Our data also suggest that those
CAD patients having IgA antibodies in their serum indi-
cate a persistent or active infection while patients having
both IgA and IgG may reveal chronicity of persistent active
infection and the presence of IgG alone reflects past infec-
tion. It has been reported that serum IgA antibody to C.
pneumoniae may be more predictive of coronary heart dis-
ease than IgG because IgA antibodies have different bio-
logical characteristics and may be better indicators of
persistent chlamydial infection [27,28]. The indication for
the past infection of C.pneumoniae was detected in four
individuals in whom both nPCR and IgG were positive
but were negative for IgA. It is interesting to note that in
Graph showing percentage of C. pneumoniae positivity in  CAD patients with serology group IgA, IgA+IgG, IgG and  with nPCR Figure 7
Graph showing percentage of C. pneumoniae positivity in 
CAD patients with serology group IgA, IgA+IgG, IgG and 
with nPCR. On Y axis % positivity in CAD patient for C. 
pneumoniae is depicted. On X-axis serological marker IgA, 
IgA+IgG, IgG with nPCR.
41.7
12
36.2
14.2
6.4 1.1
0
10
20
30
40
50
60
70
80
90
100
% positivity
IgA IgA+IgG IgG
Serological groups and nPCR
serology
nPCR
Graph showing % positivity of C. pneumoniae in CAD patients  with different smoking habits Figure 5
Graph showing % positivity of C. pneumoniae in CAD patients 
with different smoking habits. On Y axis % positivity for C. 
pneumoniae positivity is depicted. On X-axis; smoker groups 
are divided into heavy smoker, occasional smoker and never 
smoker.
65.3
26.3
10.8
0
10
20
30
40
50
60
70
80
90
100
% positivity
heavy smoker occasional
smoker  
never smoker
Smoker groups
Table 4: Comparison of baseline clinical characteristics of C. 
pneumoniae positive CAD patients and healthy controls.
CAD pt Healthy 
Control
O.R.
C.p +ve C.p +ve P value
(Mean) Age, yr. 54.19 51.34 NS
Sex
Male (%) 23(31.9) 04(11.1) 2.87 NS
Female (%) 04(21.1) 01(10.0) 2.10 NS
Smoker
Heavy (%) 17(65.3) 02(14.2) 4.57 0.019*
Occasional (%) 05(26.3) 01(10.0) 2.63 NS
Never (%) 05(10.8) 02(09.0) 1.19 NS
Alcohol
Heavy (%) 05(16.6) 02(13.3) 1.25 NS
Occasional (%) 03(20.0) 01(12.5) 1.60 NS
Never (%) 19(41.3) 02(08.6) 4.75 0.026*
Family History 05(29.4) 01(11.1) 2.64 NS
Of CAD (%)
History of BP (%) 05(41.6) 01(14.2) 2.91 NS
History of Diabetes (%) 05(50.0) 01(16.1) 3.00 NS
All groups are mentioned in absolute numbers and corresponding 
percentages in parentheses. Total number of subjects for both the 
group is different in various groups, C.p = Chlamydia pneumoniae, +ve 
= positive, O.R. = odds ratio.
Graph showing % positivity of C. pneumoniae in CAD patients  with different alcohol consumption Figure 6
Graph showing % positivity of C. pneumoniae in CAD patients 
with different alcohol consumption. On Y axis % positivity 
for C. pneumoniae is depicted. On X-axis- alcoholic groups 
divided into heavy alcoholic, occasional alcoholic and never 
taken alcohol.
16.6 20
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30
40
50
60
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Alcoholic groupsBMC Infectious Diseases 2007, 7:48 http://www.biomedcentral.com/1471-2334/7/48
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two CAD patients C. pneumoniae was detected by nPCR,
however C. pneumoniae specific IgA and IgG antibodies
were not detected. This could indicate an acute infection
where antibodies responses are yet to occur [29]. In our
study out of 71 IgA positive CAD patients, 51 were nega-
tive by nPCR. It is reported that infection with C. pneumo-
niae  is common, since seroepidemiological studies
demonstrated that 50 to 70% of adults have antibody to
C. pneumoniae and that nearly everyone acquires at least
one C. pneumoniae infection during his or her lifetime and
always it may not lead to symptomatic disease [24].
Earlier reports suggested that males are more prone to
CAD as well as C. pneumoniae infection [30], which has
also been demonstrated in our study. Further C. pneumo-
niae was detected significantly more in CAD patients who
were heavy smokers followed by occasional smokers or
non-smokers showing thereby that heavy smokers are
more prone to C. pneumoniae infection. Most of the pro-
posed proatherogenic actions of smoking, such as interfer-
ence with blood coagulation, induction of endothelial
dysfunction, and promotion of lipid peroxidation, reverse
themselves shortly after cessation of smoking. Such a
pathomechanism may be relevant to the development of
vessel pathology among smokers because of the facilitat-
ing effects of smoking on the manifestation of various
types of persistent infectious illness [12,31]. CAD patients
who were non-alcoholic showed significant higher posi-
tivity for C. pneumoniae than occasional or heavy alco-
holic. The mechanism by which alcohol consumption
reduces the risks for CAD appears to be multifactorial and
remains conjectural [32]. Although it has been reported
that long-term ethanol feeding reduces the severity of
early atherosclerotic lesions in mice and ethanol inhibits
human platelet activation and enhances endothelial fibri-
nolytic activity both of which are important for athrom-
bogenesis [33]. Further, we detected the higher prevalence
of C. pneumoniae in CAD patients who have had family
history of diabetes and high blood pressure than controls
showing thereby they are at higher risk of having CAD.
Conclusion
In conclusion, high prevalence of C. pneumoniae in CAD
patients as revealed by nPCR in our country is a matter of
concern. Positive nPCR findings in conjunction with high
C. pneumoniae specific antibody prevalence may suggest
an ongoing infection. Further studies are needed to define
and determine the clinical and prognostic implications of
such findings.
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